• search

Dishman Pharma completes US FDA inspection for Eprosartan Mesylate

Written by: Staff

Mumbai, May 05 (UNI) Dishman Pharmaceuticals&Chemicals Ltd has successfully completed US Food and Drug Administration (FDA) inspection for its facility located at, Bavla,a 100 per cent export oriented unit (EOU), to manufacture Eprosartan Mesylate, an anti hyper-tension drug, to be supplied to Solvay Pharmaceuticals, BV, a fortune 500 company.

Announcing this, the company said it is one of the two companies in the world with whom Solvay has entered into a long-term agreement for supply of newly developed molecule, whose patent is to expire in 2013.

Solvay will source its requirements for US markets from the company. It has increased the quantity of Eprosartan Mesylate to be supplied by the company to 50 per cent.

Eprosartan Mesylate is produced from three starting materials, whose process technology was developed by the company at it R&D, and Solvay has entered into long-term agreement to procure these starting materials to manufacture Eprosartan Mesylate by the second supplier from whom it is outsourcing its balance requirement of the drug.


For Daily Alerts

For Breaking News from Oneindia
Get instant news updates throughout the day.

Notification Settings X
Time Settings
Clear Notification X
Do you want to clear all the notifications from your inbox?
Settings X
We use cookies to ensure that we give you the best experience on our website. This includes cookies from third party social media websites and ad networks. Such third party cookies may track your use on Oneindia sites for better rendering. Our partners use cookies to ensure we show you advertising that is relevant to you. If you continue without changing your settings, we'll assume that you are happy to receive all cookies on Oneindia website. However, you can change your cookie settings at any time. Learn more